Comparative Analysis of CAR T Cells with Dual Specificity for CD19 and CD20
https://doi.org/10.18705/2782-3806-2024-4-5-413-420
EDN: EENWVA
Abstract
CAR T-cell therapy of patients with B-cell malignancies demonstrates high efficacy and an acceptable safety profile. However, some patients do not respond to treatment or quickly relapse. One of the reasons for an inadequate response to CAR T-cell therapy may be the emergence of cancer cells escape variants that do not express the epitope recognized by the CAR. Using CAR T-cells with dual specificity could help mitigate this issue. In this study, we developed CAR T-cells specific to human CD19 and CD20 by exploring four configurations of antigen-recognition domains: two in the biCAR format and two in the dualCAR format. Expression of two independent CARs (dualCAR) driven by a single promoter was found to be the most promising format.
Supporting agencies: The work was carried out with the financial support of the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2022301 dated 04/20/2022)
About the Authors
T. N. Belovezhets
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Belovezhets Tatyana N. - scientist, genome editing group, World Class Research Centre for Personalized Medicine.
Saint Petersburg
A. A. Gorchakov
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Gorchakov Andrey A. - Candidate of Biological Sciences, senior scientist, genome editing group, World Class Research Centre for Personalized Medicine.
Saint Petersburg
K. A. Samochernykh
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Samochernykh Konstantin A. - Doctor of Medical Sciences, Professor of the Russian Academy of Sciences, Head.
Saint Petersburg
S. V. Kulemzin
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Kulemzin Sergei V. - Candidate of Biological Sciences, senior scientist, genome editing group, World Class Research Centre for Personalized Medicine.
Akkuratova str., 2, Saint Petersburg, Russia, 197341
References
1. Awasthi R, Maier HJ, Zhang J, Lim S. Kymriah® (tisagenlecleucel) An overview of the clinical development journey of the first approved CAR-T therapy. Human vaccines & immunotherapeutics. 2023;19(1):2210046. https://doi.org/10.1080/21645515.2023.2210046
2. Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nature reviews. Drug discovery. 2023;22(12):976–995. https://doi.org/10.1038/s41573-023-00807-1
3. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nature reviews. Clinical oncology. 2019;16(6): 372–385. https://doi.org/10.1038/s41571019-0184-6
4. Cronk RJ, Zurko J, Shah NN. Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. Cancers. 2020;12(9):2523. https://doi.org/10.3390/cancers12092523
5. Kulemzin SV, Chikaev NA, Volkova OYu, et al. A modular system of lentiviral vectors for working with chimeric antigenic receptors. Bioorganicheskaya ximiya=Russian Journal of Bioorganic Chemistry. 2017;43(2):124–132. In Russian
6. Belovezhets T, Kulemzin S, Volkova O, et al. Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties. International journal of molecular sciences. 2023;24(4):3698. https://doi.org/10.3390/ijms24043698
7. Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126(8):983–992. https://doi.org/10.1182/blood-2015-02-629527
8. Wang L, Fang C, Kang Q, et al. Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial. Blood cancer journal. 2024;14(1):130. https://doi.org/10.1038/s41408-024-01105-8
9. Larson SM, Walthers CM, Ji B, et al. CD19/ CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer discovery. 2023;13(3):580–597. https://doi.org/10.1158/2159-8290.CD-22-0964
10. Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature medicine. 2020;26(10):1569– 1575. https://doi.org/10.1038/s41591-020-1081-3
11. Qin H, Ramakrishna S, Nguyen S, et al. Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22. Molecular therapy oncolytics. 2018;11:127–137. https://doi.org/10.1016/j.omto.2018.10.006
12. Qin H, Nguyen SM, Ramakrishna S, et al. Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19+CD22+, CD19-, and CD22Pre-B Leukemia. Blood. 2017;130:810-810.
13. Wang Y, Zhong K, Ke J, et al. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. Cytotherapy. 2021;23(8): 715– 723. https://doi.org/10.1016/j.jcyt.2021.02.117
14. Larson SM, Walthers CM, Ji B, et al. CD19/ CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer discovery. 2023;13(3):580–597. https://doi.org/10.1158/2159-8290.CD-22-0964
15. Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature medicine. 2020;26(10):1569– 1575. https://doi.org/10.1038/s41591-020-1081-3
16. Gomes-Silva D, Mukherjee M, Srinivasan M, et al. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell reports. 2017;21(1):17–26. https://doi.org/10.1016/j.celrep.2017.09.015
Review
For citations:
Belovezhets T.N., Gorchakov A.A., Samochernykh K.A., Kulemzin S.V. Comparative Analysis of CAR T Cells with Dual Specificity for CD19 and CD20. Russian Journal for Personalized Medicine. 2024;4(5):413-420. (In Russ.) https://doi.org/10.18705/2782-3806-2024-4-5-413-420. EDN: EENWVA
Views:
127
Email this article 